Skip to main content

ARS Pharmaceuticals, Inc 10-Q for FY2026 Q3

ARS Pharmaceuticals, Inc. (SPRY)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

ARS Pharmaceuticals, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

ARS Pharmaceuticals reported nine-month 2026 revenue of $94.0 million, versus $56.2 million in 2025, and net loss of $158.5 million. neffy generated $77.1 million in U.S. net product revenue, while cash, cash equivalents and short-term investments totaled $138.4 million at September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$37.71M
up 16.0% from $32.5M a year earlier
Net loss
$35.59M
compared with a net loss of $51.15M a year earlier
Diluted EPS
-$0.36
compared with -$0.52 a year earlier